Saturday 17 October 2026
Export OKUR’s income statement to Excel — free account
OnKure Therapeutics, Inc.
OKUR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 72.8% and free cash flow grew 22.1%, each against the same quarter a year earlier.
2.10
0.03
−1.41%
Follow OKUR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(90.36%) | (74.39%) | (42.73%) | (46.91%) | |
| (84.34%) | (67.24%) | (39.35%) | (44.24%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(96.15%) | (107.17%) | (31.99%) | (34.24%) | |
Free Cash Flow per Share |
(4.71) | (3.84) | (3.71) | (0.96) | |
Free Cash Flow |
(63.72) | (51.87) | (50.79) | (47.86) | |
Capital Expenditures |
(0.05) | (0.05) | (0.03) | (0.02) | |
| Other line items | |||||
Cash ROIC |
(46.59%) | (45.02%) | (13.49%) | (13.73%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.00 | 0.87 | 0.86 | 0.81 | |
Depreciation/Fixed assets |
1.18 | 1.34 | 1.58 | 1.83 | |
Capex/Depreciation |
(0.06) | (0.06) | (0.04) | (0.03) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.71) | (3.83) | (3.71) | (0.96) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates